ABBVIE INC.
Last · NYSE$283.52+9.165 (+3.34%)close · yahoo · 7h ago
Vol 4.20M ≈ 1.19B
MA10MA20MA50
Market cap$501.02B1.77B sh
P/E · TTM80.1fwd 17.5 · eps 3.54
Beta0.23vs S&P 500
Div yield2.49%annual · TTM
52w range
$190.75$285.40
Volume4.2Msession
Issuer
Legal nameABBVIE INC.
HQUnited States (US)
ListingUS ABBV
ISINUS00287Y1091
SectorHealthcare
IndustryDrugs (Pharmaceutical)
SIC2834
CurrencyUSD
Entity registrysec:0001551152
CIK0001551152
Websitewww.abbvie.com
Employees57,000
AddressAbbVie, Inc. 1 North Waukegan Road 60064-6400, North Chicago +847 932 7900
| Revenue | $64.4B |
|---|---|
| Operating income | $16.9B |
| Net income | $6.3B |
| Free cash flow | $18.2B |
| Operating margin | 26.2% |
| Net margin | 9.7% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
10-K · 2026-02-20
From latest 10-K · 2026-02-20
- Revenue Growth
- Skyrizi Rinvoq Concentration
- Medicare Price Setting
- Patent Exclusivity
- Biosimilar Risk
- Debt Leverage
- Pipeline Execution
Red flags
- Skyrizi and Rinvoq together generated approximately 42% of 2025 net revenue, creating material concentration in two immunology products.
- Total long-term debt and finance lease obligations were $65.0 billion at year-end 2025, including $6.1 billion due within one year, versus $5.2 billion of cash and equivalents.
- AbbVie recorded $6.5 billion of contingent-consideration fair-value expense, $7.4 billion of intangible amortization and $847 million of intangible impairment in 2025; contingent consideration liabilities were $25.4 billion at year-end.
- Imbruvica, Vraylar, Linzess and Botox are scheduled for Medicare government price-setting beginning in 2026, 2027, 2027 and 2028, respectively, potentially accelerating revenue erosion before patent expiry.
- 2025 diluted EPS was only $2.36, down from $2.39 in 2024 and $2.72 in 2023, despite 9% revenue growth, reflecting the burden of amortization, financing and acquisition-related items.
Upcoming earnings
FRI.30OCT
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$3.79
Est. revenue
17.3B
Earnings transcripts
Press & signals
- Satelight
Fantasy M&A: the recipe for a European champion
- Satelight
Retrieval-grounded robot program generation and simulation-based correction via Model Context Protocol
- Satelight
Psychedelic drugs are going mainstream
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags
Showing 5 of 164 filings